In this video summary, Dr. Ignasi Figueras from the University of Barcelona and Dr. Alexandra Golant from Mount Sinai Hospital, USA, discussed the disease burden, pathophysiology, and effectiveness of Dupixent—the first treatment approved in the European Union (EU) for severe atopic dermatitis (AD) in children between the ages of 6 months to 11 years who are candidates for systemic therapy.